GSK plc announced on April 20, 2026, that Blenrep (belantamab mafodotin) has been approved in China for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, showing a 42% reduction in death risk and nearly tripled median progression-free survival compared to standard treatments.